G56W1

· Shenzhen Salubris Pharmaceuticals Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for G56W1, covering 2018-10-25 to 2018-10-25. Get the full timeline:

Most recent: Clinical Trial Update: G56W1 in Women With Postmenopausal Osteoporosis [Phase 1, Phase 2]